The usefulness of D-dimer in diagnosis and prediction of venous thromboembolism in patients with abdominal malignancy

Kwietniak, Marcin; Al-Amawi, Tariq; Błaszkowski, Tomasz; Sulżyc-Bielicka, Violetta; Kładny, Józef

doi:10.5604/01.3001.0010.1018

Cited by 6 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…D-dimer is the cleavage product of cross-linked fibrin that is formed by activation of the coagulation system, which signals hyperfibrinolysis in response to clot activation and fibrin formation (1). Elevated levels of D-dimer have been detected in patients exhibiting diffuse intravascular coagulation (2), vascular occlusion crisis in sickle cell disease (3), thromboembolic events (4,5) and myocardial infarction (6). D-dimer is a widely used biomarker for indicating the activation of coagulation and fibrinolysis (7,8).…”

Section: Introductionmentioning

confidence: 99%

D‑dimer as a potential clinical marker for predicting metastasis and progression in cancer

et al. 2018

View full text Add to dashboard Cite

D-dimer is a widely used biomarker for indicating the activation of coagulation and fibrinolysis, and is reported to serve important roles in cancer progression. The aim of the current retrospective study was to investigate the association of D-dimer plasma level with the development of various cancers. Patients with breast (n=86), gastric (n=317), pancreatic (n=37), colon (n=153) and rectal (n=137) cancers and 92 healthy volunteers were assessed in the present study. Plasma levels of D-dimer in the patients and healthy controls were measured by immunoturbidimetric assays. The association of D-dimer levels with the clinicopathological features of patients were also determined. The plasma levels of D-dimer were significantly higher in patients with breast cancer (P=0.0022), gastric cancer (P<0.0001), pancreatic cancer (P=0.0003), colon cancer (P=0.0001) and rectal cancer (P=0.0028), compared with the healthy controls. It was also determined that the plasma D-dimer levels were positively associated with clinical cancer stage (P<0.05) and metastasis (P<0.05). These findings suggested that the plasma D-dimer level may be used as marker for predicting cancer metastasis and progression.

show abstract

Section: Introductionmentioning

confidence: 99%

D‑dimer as a potential clinical marker for predicting metastasis and progression in cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…FIB and D-dimer are speci c indicators of hypercoagulability. Hypercoagulability in patients with malignant tumors can promote the formation of tumor thrombi and cause secondary hyper brinolysis [6]. FIB is the main coagulation factor in plasma, and its normal concentration is about 2 to 4 g/L [7].…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy for Esophageal Squamous Cell Carcinoma Concomitant With Hypoproteinemia: a Case Report

Jia

Wang

Yang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Malignant tumors frequently combined with hyperfibrinogenemia, rarely with hypofibrinogenemia.Case presentation: This study reports a 60-year-old male patient of mid-thoracic esophageal squamous cell carcinoma (ESCC) with hypofibrinogenemia who presented at our hospital because of a swallowing disorder and dull pain in the upper abdomen. An initial test indicated his plasma fibrinogen (FIB) level was 0.88 g/L (reference range: 2.38–4.98 g/L). After multiple infusions of fresh plasma and supplements of FIB and cryoprecipitate, he maintained a FIB level above 1.0 g/L. We administered radical radiotherapy (RT) for the ESCC, and his FIB level gradually normalized during the RT period. The symptoms from ESCC gradually resolved, and we classified the patient as having stable disease at the end of the RT period. After 10 months follow-up, the patient have achieved partial response (PR). At that time, the patient had no increased tendency for bleeding and his FIB level was 0.97 g/L. At the last follow-up, the patient has survival about 18 months. Conclusions: it was considered the hypofibrinogenemia in this ESCC patient to be a consequence of paraneoplastic syndrome.

show abstract

“…D-dimer is a fibrin degradation product, and abnormal plasma D-dimer levels have been detected in patients with thromboembolic events [ 5 , 6 ], myocardial infarction [ 7 ], infection [ 8 ], autoimmune diseases [ 9 ], and various carcinomas [ 10 – 13 ]. Recent studies further showed that elevated plasma D-dimer levels can predict poor prognosis in patients with liver diseases [ 14 – 16 ].…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, it is important to establish an objective, accurate, and simple prognostic model that can identify high-risk patients and help guide clinicians when adjusting treatment strategies. D-dimer is a fibrin degradation product, and abnormal plasma D-dimer levels have been detected in patients with thromboembolic events [5,6], myocardial infarction [7], infection [8], autoimmune diseases [9], and various carcinomas [10][11][12][13]. Recent studies further showed that elevated plasma D-dimer levels can predict poor prognosis in patients with liver diseases [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

D-Dimer-to-Albumin Ratio: A Novel Indicator to Predict Poor Outcomes in Patients with HBV-Associated Decompensated Cirrhosis

Sun

Ding

Mao

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Background. The purpose of the present study was to investigate the impact of D-dimer-to-albumin ratio (DAR) on outcomes in patients with hepatitis B virus-associated decompensated cirrhosis (HBV-DeCi). Methods. A total of 172 HBV-DeCi patients were enrolled. Logistic regression was used to explore the association between DAR and 30-day mortality. The area under the receiver operating characteristic curve (AUC) was used to evaluate the performance of DAR for predicting mortality. Results. The 30-day mortality was 19.8%. DAR was clearly higher in the nonsurvivors compared with the survivors, and increasing DAR was associated with an increasing risk of death. DAR was independently associated with mortality and its AUC for mortality was equivalent to that for Model for End-Stage Liver Disease score. Conclusions. DAR may be a potential prognostic marker for mortality in HBV-DeCi patients.

show abstract

The usefulness of D-dimer in diagnosis and prediction of venous thromboembolism in patients with abdominal malignancy

Cited by 6 publications

References 9 publications

D‑dimer as a potential clinical marker for predicting metastasis and progression in cancer

D‑dimer as a potential clinical marker for predicting metastasis and progression in cancer

Radiotherapy for Esophageal Squamous Cell Carcinoma Concomitant With Hypoproteinemia: a Case Report

D-Dimer-to-Albumin Ratio: A Novel Indicator to Predict Poor Outcomes in Patients with HBV-Associated Decompensated Cirrhosis

Contact Info

Product

Resources

About